Sean Lawrence Finnerty, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 801 Middleford Rd, Seaford, DE 19973 Phone: 302-629-6611 |
Thomas A Tarter, MD Emergency Medicine - Emergency Medical Services Medicare: Not Enrolled in Medicare Practice Location: 801 Middleford Rd, Seaford, DE 19973 Phone: 302-629-6611 |
Hassan Farhat, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 801 Middleford Rd, Seaford, DE 19973 Phone: 302-629-6611 |
News Archive
Omeros Corporation today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system, has received orphan drug designation from the U.S. Food and Drug Administration for prevention of complement-mediated thrombotic microangiopathies.
"Sri Lanka has long enjoyed a low 0.1 percent HIV prevalence but, as the number of fresh infections rises steadily, experts are calling for a change in the country's archaic laws that make sex work illegal and criminalizes homosexual activity," Inter Press Service reports.
Integrated Document Solutions, a pioneer in delivering healthcare information and applications via cloud computing since 2003, today released the latest version of its AbbaDox modular healthcare workflow and documentation portal, featuring cross-platform compatibility and a new streamlined user interface. It is the company's fifth-generation cloud computing solution.
Bayer HealthCare initiated and will coordinate a newly founded pan-European consortium, named European Lead Factory, which has been launched to enhance early drug discovery addressing the need for innovative drugs. The new five-year project will create an exceptional small molecule library collection allowing drug discovery on innovative and promising targets from pharma companies and academia.
W. L. Gore & Associates (Gore) reported the complete enrollment in a post-market approval study designed to better characterize the performance of the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface in treating peripheral vascular disease (PVD) of the superficial femoral artery (SFA). The 11 participating sites enrolled a total of 120 patients in the Gore VIPER (GOREĀ® VIABAHNĀ® Endoprosthesis with Heparin Bioactive Surface for SuPERficial Femoral Artery Endoluminal Bypass) Study since initiation.
› Verified 9 days ago